This osteoarthritis (OA) collaboration will continue the work in two research programs that were initiated in the first collaboration with Pfizer that started in October 2002.
The two-year collaboration provides Pfizer with access to ChondroGene’s unique database of OA tissue-specific clinical and gene expression information to identify potential novel therapeutic targets for OA. The agreement with Pfizer will also allow ChondroGene to accelerate its ongoing OA biomarker research program.
Development of new biomarkers is essential for the early diagnosis of OA as well as for validating the effectiveness of potential disease-modifying therapies. The two-year collaboration is valued at up to $7.35 million, compared to $4.7 million for the initial collaboration.
“We are pleased with the progress made in our initial collaboration and look forward to continuing our relationship with Pfizer in this second agreement,” stated Dr K Wayne Marshall, president and CEO of ChondroGene. “We are excited to be working together to develop novel biomarkers for osteoarthritis, an epidemic disease that places a crippling burden on patients, their families and healthcare resources.”